SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David S. who wrote (3631)1/17/1998 9:15:00 PM
From: JOHN W.  Read Replies (2) of 6136
 
"Improving HIV-1 Protease Inhibitor May Be Feasible"
Reuters Health Information services (01/15/98)
Researchers at Vanderbilt University claim that the
bioavailablity of HIV-1 protease inhibitors may be boosted by
inhibition of P-glycoprotein, a multidrug transporter. In the
January issue of the Journal of Clinical Investigations, the
researchers suggest that HIV-1 protease inhibitors, which have
limited oral absorption and variable tissue distribution, may be
P-glycoprotein substrates. Testing indinavir, nelfinavir, and
saquinavir in an in vitro system, the researchers found that all
three compounds are transported by P-glycoproteins. According
tothe researchers, targeted pharmacologic inhibition of
P-glycoprotein transport activity may allow for higher
concentrations of HIV-1 protease inhibitors.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News